ClinicalTrials.Veeva

Menu

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Celgene logo

Celgene

Status and phase

Active, not recruiting
Phase 2
Phase 1

Conditions

Multiple Myeloma

Treatments

Drug: Isatuximab
Drug: CC-92480
Drug: Dexamethasone
Drug: Elotuzumab
Drug: Bortezomib
Drug: Carfilzomib
Drug: Daratumumab

Study type

Interventional

Funder types

Industry

Identifiers

NCT03989414
2023-505219-19 (Registry Identifier)
U1111-1233-5619 (Other Identifier)
CC-92480-MM-002

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

Enrollment

424 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

• Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2

For participants in Cohorts A, B, C, D, E, F, H, I, J, and K the following inclusions will also apply:

  • Documented diagnosis of multiple myeloma (MM) and measurable disease
  • Documented disease progression during or after their last antimyeloma regimen
  • Achieved a response (minimal response [MR] or better) to at least 1 prior treatment regimen

Exclusion criteria

  • Plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) or clinically significant amyloidosis
  • Known central nervous system (CNS) involvement with myeloma
  • Received immunosuppressive medication within the last 14 days of initiating study treatment
  • Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to enrollment

Other protocol-defined inclusion/exclusion criteria apply

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

424 participants in 15 patient groups

Cohort A: CC-92480 with bortezomib and dexamethasone
Experimental group
Treatment:
Drug: Bortezomib
Drug: Dexamethasone
Drug: CC-92480
Cohort C: CC-92480 with carfilzomib and dexamethasone
Experimental group
Treatment:
Drug: Carfilzomib
Drug: Carfilzomib
Drug: Dexamethasone
Drug: CC-92480
Cohort H: CC-92480 with elotuzumab and dexamethasone
Experimental group
Treatment:
Drug: Elotuzumab
Drug: Dexamethasone
Drug: CC-92480
Cohort I: CC-92480 with isatuximab and dexamethasone
Experimental group
Treatment:
Drug: Dexamethasone
Drug: CC-92480
Drug: Isatuximab
Cohort D: CC-92480 with bortezomib and dexamethasone
Experimental group
Treatment:
Drug: Bortezomib
Drug: Dexamethasone
Drug: CC-92480
Cohort F: CC-92480 with carfilzomib and dexamethasone
Experimental group
Treatment:
Drug: Carfilzomib
Drug: Carfilzomib
Drug: Dexamethasone
Drug: CC-92480
Cohort J: CC-92480 with elotuzumab and dexamethasone
Experimental group
Treatment:
Drug: Elotuzumab
Drug: Dexamethasone
Drug: CC-92480
Cohort K: CC-92480 with isatuximab and dexamethasone
Experimental group
Treatment:
Drug: Dexamethasone
Drug: CC-92480
Drug: Isatuximab
Cohort G: CC-92480 with bortezomib and dexamethasone
Experimental group
Treatment:
Drug: Bortezomib
Drug: Dexamethasone
Drug: CC-92480
Subcohort B1: CC-92480 with daratumumab and dexamethasone
Experimental group
Treatment:
Drug: Daratumumab
Drug: Dexamethasone
Drug: CC-92480
Subcohort B2: CC-92480 with daratumumab and dexamethasone
Experimental group
Treatment:
Drug: Daratumumab
Drug: Dexamethasone
Drug: CC-92480
Subcohort B3: CC-92480 with daratumumab and dexamethasone
Experimental group
Treatment:
Drug: Daratumumab
Drug: Dexamethasone
Drug: CC-92480
Subcohort E1: CC-92480 with daratumumab and dexamethasone
Experimental group
Treatment:
Drug: Daratumumab
Drug: Dexamethasone
Drug: CC-92480
Subcohort E2: CC-92480 with daratumumab and dexamethasone
Experimental group
Treatment:
Drug: Daratumumab
Drug: Dexamethasone
Drug: CC-92480
Subcohort E3: CC-92480 with daratumumab and dexamethasone
Experimental group
Treatment:
Drug: Daratumumab
Drug: Dexamethasone
Drug: CC-92480

Trial contacts and locations

49

Loading...

Central trial contact

First line of the email MUST contain the NCT# and Site #.; BMS Study Connect Contact Center www.BMSStudyConnect.com

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems